Welcome to our dedicated page for XPHYF news (Ticker: XPHYF), a resource for investors and traders seeking the latest updates and insights on XPHYF stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect XPHYF's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of XPHYF's position in the market.
Summary not available.
XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF) has completed a corporate rebranding and launched a new website as of March 4, 2021. This rebranding underscores its commitment to advancing product development, notably its rapid point-of-care COVID-19 PCR test system, which is nearing ISO certification and CE-IVD approval. The company aims to enhance value through commercialization and innovation, as it targets the European market for medical products. However, it cautions that its COVID-19 testing products are still under regulatory review and not yet approved.
XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) has issued a statement addressing recent promotional activities, particularly a newsletter from WallStreetAlerts. The company acknowledges its previous non-compliance with CSE disclosure requirements regarding third-party promotional contracts but has now submitted the necessary forms. To ensure transparency, XPhyto plans to adopt a public disclosure policy for promotional communications, requiring board and legal approval. Over the past year, XPhyto paid approximately $4.94 million to third-party providers. The company clarifies that its COVID-19 tests are not yet approved and do not claim to cure the virus.
XPhyto Therapeutics Corp (CSE:XPHY, OTCQB:XPHYF) has placed its first order for Covid-ID Lab, a rapid point-of-care SARS-CoV-2 (COVID-19) RT-PCR test system, consisting of 9,600 tests. The tests will be manufactured in Germany, with delivery expected by mid-March 2021. XPhyto aims to launch the product in Europe by April 2021, targeting regulatory approval for medical use. Additionally, the company is developing oral biosensor tests for various infectious diseases and plans to commercialize its first biosensor product in the latter half of 2021.
XPhyto Therapeutics (CSE:XPHY / OTCQB:XPHYF) has established a commercial team to launch its point-of-care SARS-CoV-2 RT-PCR test, Covid-ID Lab, with expected regulatory approvals approaching. Developed in collaboration with 3a-diagnostics, the test is designed for rapid and accurate COVID-19 screening, with its initial launch in Europe targeted for April 2021. The team boasts extensive experience in medical diagnostics, aiming to leverage their expertise for effective commercialization. Additionally, XPhyto is developing a range of oral biosensor tests, with market introductions anticipated later in 2021.
XPhyto Therapeutics Corp (CSE:XPHY, OTCQB:XPHYF, FSE:4XT) announced a lawsuit against its German subsidiary, Vektor Pharma TF GMBH. The claim, made by a former client, alleges a breach of a development agreement with damages estimated at 1 million Euros. XPhyto believes the claim lacks merit and will defend Vektor vigorously. They filed a notice of defense in a German court. The corporation does not expect the lawsuit to materially impact its business. Updates will be provided as the case progresses.
XPhyto Therapeutics Corp (CSE:XPHY, OTCQB:XPHYF) has successfully completed all actions for its European regulatory application for the Covid-ID Lab, a rapid point-of-care SARS-CoV-2 RT-PCR Test System. 3a-diagnostics GmbH, XPhyto's partner, anticipates receiving ISO 13485 certification by late February and CE-IVD approval by early March, with a sales launch in Europe planned for April 2021. Additionally, XPhyto is developing oral biosensor tests targeting various infectious diseases, aiming for a product launch in the second half of 2021.
XPhyto Therapeutics Corp has announced the addition of mescaline production to its psychedelic medicine programs through its subsidiary, XPhyto Laboratories. This expansion aligns with the company's goal to develop industrial-scale production and deliver pharmaceutical-grade mescaline, recognized for its potential in treating addiction and depression. The company aims to standardize dosage formulations for clinical and therapeutic use. XPhyto believes this move will significantly enhance its portfolio and market opportunities in the psychedelic drug space.
XPhyto Therapeutics Corp (CSE:XPHY / OTCQB:XPHYF / FSE:4XT) will present at the virtual LD Micro Main Event (XIII) on December 15, 2020, at 1:20 p.m. Eastern time. CEO Hugh Rogers will lead the presentation, and a live audio webcast will be available. Recent highlights include the development of an RT-PCR test for COVID-19 detection and partnerships for psilocybin API production. XPhyto focuses on drug delivery, diagnostics, and emerging pharmaceuticals, with operations in North America and Europe, targeting regulatory approvals in European markets.
XPhyto Therapeutics Corp (CSE:XPHY, OTCQB:XPHYF) announced an agreement for a $3 million issuance of unsecured convertible debentures. The investor specializes in manufacturing medical products in Europe and the Middle East. Proceeds will fund development of oral dissolvable and transdermal drug formulations, diagnostic products, and psychedelic APIs. The debentures carry an 8% interest rate, maturing in two years, and are convertible into common shares at $1.77. The offering awaits CSE approval, with a statutory hold period applicable.